Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Multicenter Study of Gleolan (Aminolevulinic Acid Hydrochloride) to Enhance Visualization of Tumor in Patients With Newly Diagnosed or Recurrent Meningiomas

NCT04305470 is registered in ClinicalTrials.gov with NX Development Corp as lead sponsor.

NCT NCT04305470
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04305470 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Multicenter Study of Gleolan (Aminolevulinic Acid Hydrochloride) to Enhance Visualization of Tumor in Patients With Newly Diagnosed or Recurrent Meningiomas
Lead sponsor
NX Development Corp
Phase
Phase 3
Overall status
Completed
Start date
October 28, 2020
Completion date
December 13, 2022
Enrollment
108 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

meningioma